Search Results - "FAYAD, Luis"

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial by Westin, Jason R, MD, Chu, Fuliang, PhD, Zhang, Min, PhD, Fayad, Luis E, MD, Kwak, Larry W, Prof, Fowler, Nathan, MD, Romaguera, Jorge, Prof, Hagemeister, Fredrick, Prof, Fanale, Michelle, MD, Samaniego, Felipe, MD, Feng, Lei, MS, Baladandayuthapani, Veerabhadran, PhD, Wang, Zhiqiang, PhD, Ma, Wencai, PhD, Gao, Yanli, MS, Wallace, Michael, Prof, Vence, Luis M, PhD, Radvanyi, Laszlo, Prof, Muzzafar, Tariq, MD, Rotem-Yehudar, Rinat, PhD, Davis, R Eric, MD, Neelapu, Sattva S, Dr

“…Summary Background Endogenous or iatrogenic antitumour immune responses can improve the course of follicular lymphoma, but might be diminished by immune…”
Get full text

Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma by Strati, Paolo, Varma, Ankur, Adkins, Sherry, Nastoupil, Loretta J, Westin, Jason, Hagemeister, Fredrick B, Fowler, Nathan H, Lee, Hun J, Fayad, Luis E, Samaniego, Felipe, Ahmed, Sairah, Chen, Yiming, Horowitz, Sandra, Arafat, Sara, Johncy, Swapna, Kebriaei, Partow, Mulanovich, Victor Eduardo, Ariza Heredia, Ella, Neelapu, Sattva S

“…Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 may be associated with long-term adverse effects such as cytopenia and immune deficiency. In…”
Get full text

Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection by Strati, Paolo, Nastoupil, Loretta J., Fayad, Luis E., Samaniego, Felipe, Adkins, Sherry, Neelapu, Sattva S.

Get full text

Double hit lymphoma: the MD Anderson Cancer Center clinical experience by Oki, Yasuhiro, Noorani, Mansoor, Lin, Pei, Davis, Richard E., Neelapu, Sattva S., Ma, Long, Ahmed, Mohamed, Rodriguez, Maria Alma, Hagemeister, Fredrick B., Fowler, Nathan, Wang, Michael, Fanale, Michelle A., Nastoupil, Loretta, Samaniego, Felipe, Lee, Hun J., Dabaja, Bouthaina S., Pinnix, Chelsea C., Medeiros, Leonard J., Nieto, Yago, Khouri, Issa, Kwak, Larry W., Turturro, Francesco, Romaguera, Jorge E., Fayad, Luis E., Westin, Jason R.

“…Summary We report our experience with 129 cases of double hit lymphoma (DHL), defined as B‐cell lymphoma with translocations and/or extra signals involving MYC…”
Get full text

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial by Fowler, Nathan H, Dr, Davis, R Eric, MD, Rawal, Seema, PhD, Nastoupil, Loretta, MD, Hagemeister, Fredrick B, Prof, McLaughlin, Peter, Prof, Kwak, Larry W, Prof, Romaguera, Jorge E, Prof, Fanale, Michelle A, MD, Fayad, Luis E, MD, Westin, Jason R, MD, Shah, Jatin, MD, Orlowski, Robert Z, Prof, Wang, Michael, Prof, Turturro, Francesco, Prof, Oki, Yasuhiro, MD, Claret, Linda C, RN, Feng, Lei, MS, Baladandayuthapani, Veerabhadran, PhD, Muzzafar, Tariq, MD, Tsai, Kenneth Y, MD, Samaniego, Felipe, MD, Neelapu, Sattva S, MD

“…Summary Background Standard treatments for indolent non-Hodgkin lymphomas are often toxic, and most patients ultimately relapse. Lenalidomide, an…”
Get full text

A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy by Stein-Thoeringer, Christoph K., Saini, Neeraj Y., Zamir, Eli, Blumenberg, Viktoria, Schubert, Maria-Luisa, Mor, Uria, Fante, Matthias A., Schmidt, Sabine, Hayase, Eiko, Hayase, Tomo, Rohrbach, Roman, Chang, Chia-Chi, McDaniel, Lauren, Flores, Ivonne, Gaiser, Rogier, Edinger, Matthias, Wolff, Daniel, Heidenreich, Martin, Strati, Paolo, Nair, Ranjit, Chihara, Dai, Fayad, Luis E., Ahmed, Sairah, Iyer, Swaminathan P., Steiner, Raphael E., Jain, Preetesh, Nastoupil, Loretta J., Westin, Jason, Arora, Reetakshi, Wang, Michael L., Turner, Joel, Menges, Meghan, Hidalgo-Vargas, Melanie, Reid, Kayla, Dreger, Peter, Schmitt, Anita, Müller-Tidow, Carsten, Locke, Frederick L., Davila, Marco L., Champlin, Richard E., Flowers, Christopher R., Shpall, Elizabeth J., Poeck, Hendrik, Neelapu, Sattva S., Schmitt, Michael, Subklewe, Marion, Jain, Michael D., Jenq, Robert R., Elinav, Eran

“…Increasing evidence suggests that the gut microbiome may modulate the efficacy of cancer immunotherapy. In a B cell lymphoma patient cohort from five centers…”
Get full text

Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma by Strati, Paolo, Ahmed, Sairah, Furqan, Fateeha, Fayad, Luis E., Lee, Hun J., Iyer, Swaminathan P., Nair, Ranjit, Nastoupil, Loretta J., Parmar, Simrit, Rodriguez, Maria A., Samaniego, Felipe, Steiner, Raphael E., Wang, Michael, Pinnix, Chelsea C., Horowitz, Sandra B., Feng, Lei, Sun, Ryan, Claussen, Catherine M., Hawkins, Misha C., Johnson, Nicole A., Singh, Prachee, Mistry, Haleigh, Johncy, Swapna, Adkins, Sherry, Kebriaei, Partow, Shpall, Elizabeth J., Green, Michael R., Flowers, Christopher R., Westin, Jason, Neelapu, Sattva S.

“…Corticosteroids are commonly used for the management of severe toxicities associated with chimeric antigen receptor (CAR) T-cell therapy. However, it remains…”
Get full text

Breast Implant–Associated Anaplastic Large-Cell Lymphoma: Long-Term Follow-Up of 60 Patients by MIRANDA, Roberto N, ALADILY, Tariq N, SHIFRIN, David A, O'MALLEY, Dennis P, CHEAH, Chan Y, BACCHI, Carlos E, GUALCO, Gabriela, SHIYONG LI, KEECH, John A, HOCHBERG, Ephram P, CARTY, Matthew J, HANSON, Summer E, PRINCE, H. Miles, MUSTAFA, Eid, SANCHEZ, Steven, MANNING, John T, XU-MONETTE, Zijun Y, MIRANDA, Alonso R, FOX, Patricia, BASSETT, Roland L, CASTILLO, Jorge J, BELTRAN, Brady E, DE BOER, Jan Paul, KANAGAL-SHAMANNA, Rashmi, CHAKHACHIRO, Zaher, DONGJIU YE, CLARK, Douglas, YOUNG, Ken H, MEDEIROS, L. Jeffrey, DE JONG, Daphne, FAYAD, Luis E, AMIN, Mitual B, HAIDERI, Nisreen, BHAGAT, Govind, BROOKS, Glen S

“…Breast implant-associated anaplastic large-cell lymphoma (ALCL) is a recently described clinicopathologic entity that usually presents as an…”
Get full text

B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome by Li, Shaoying, Lin, Pei, Fayad, Luis E, Lennon, Patrick A, Miranda, Roberto N, Yin, C Cameron, Lin, E, Medeiros, L Jeffrey

“…B-cell lymphomas with MYC/8q24 rearrangement and IGH@BCL2/t(14;18)(q32;q21), also known as double-hit or MYC/BCL2 B-cell lymphomas, are uncommon neoplasms. We…”
Get full text

Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study by Sehn, Laurie H, Goy, Andre, Offner, Fritz C, Martinelli, Giovanni, Caballero, M Dolores, Gadeberg, Ole, Baetz, Tara, Zelenetz, Andrew D, Gaidano, Gianluca, Fayad, Luis E, Buckstein, Rena, Friedberg, Jonathan W, Crump, Michael, Jaksic, Branimir, Zinzani, Pier Luigi, Padmanabhan Iyer, Swaminathan, Sahin, Deniz, Chai, Akiko, Fingerle-Rowson, Günter, Press, Oliver W

“…Obinutuzumab (GA101), a novel glycoengineered type II anti-CD20 monoclonal antibody, demonstrated responses in single-arm studies of patients with…”
Get full text

Predictors of Radiation Pneumonitis in Patients Receiving Intensity Modulated Radiation Therapy for Hodgkin and Non-Hodgkin Lymphoma by Pinnix, Chelsea C., MD, PhD, Smith, Grace L., MD, PhD, Milgrom, Sarah, MD, Osborne, Eleanor M., MD, Reddy, Jay P., MD, PhD, Akhtari, Mani, MD, Reed, Valerie, MD, Arzu, Isidora, MD, Allen, Pamela K., PhD, Wogan, Christine F., MS, Fanale, Michele A., MD, Oki, Yasuhiro, MD, Turturro, Francesco, MD, Romaguera, Jorge, MD, Fayad, Luis, MD, Fowler, Nathan, MD, Westin, Jason, MD, Nastoupil, Loretta, MD, Hagemeister, Fredrick B., MD, Rodriguez, M. Alma, MD, Ahmed, Sairah, MD, Nieto, Yago, MD, PhD, Dabaja, Bouthaina, MD

“…Purpose Few studies to date have evaluated factors associated with the development of radiation pneumonitis (RP) in patients with Hodgkin lymphoma (HL) and…”
Get full text

The Utility of Point of Care Biomarkers to Detect Cardiotoxicity during Anthracycline Chemotherapy: A Feasibility Study by Lenihan, Daniel J., MD, Stevens, Patrick L, MD, Massey, Mona, RN, BSN, Plana, Juan Carlos, MD, Araujo, Dejka M, MD, Fanale, Michelle A, MD, Fayad, Luis E, MD, Fisch, Michael J, MD, MPH, Yeh, Edward TH, MD

“…Highlights • Cardiac biomarkers, specifically BNP, can be part of an effective screening strategy for Anthracycline-related cardiotoxicity • In this study,…”
Get full text

The risk of central nervous system relapses in patients with peripheral T-cell lymphoma by Chihara, Dai, Fanale, Michelle A, Miranda, Roberto N, Noorani, Mansoor, Westin, Jason R, Nastoupil, Loretta J, Hagemeister, Fredrick B, Fayad, Luis E, Romaguera, Jorge E, Samaniego, Felipe, Turturro, Francesco, Lee, Hun J, Neelapu, Sattva S, Rodriguez, M Alma, Wang, Michael, Fowler, Nathan H, Davis, Richard E, Medeiros, L Jeffrey, Oki, Yasuhiro

“…We performed a retrospective analysis to identify risk factors and survival outcome for central nervous system (CNS) relapse of peripheral T-cell lymphoma…”
Get full text

Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B‐cell non‐Hodgkin lymphoma by Dang, Nam H., Ogura, Michinori, Castaigne, Sylvie, Fayad, Luis E., Jerkeman, Mats, Radford, John, Pezzutto, Antonio, Bondarenko, Igor, Stewart, Douglas A., Shnaidman, Michael, Sullivan, Sharon, Vandendries, Erik, Tobinai, Kensei, Ramchandren, Radhakrishnan, Hamlin, Paul A., Giné, Eva, Ando, Kiyoshi

Get full text

Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial by Wang, Michael L, Prof, Lee, Hun, MD, Chuang, Hubert, MD, Wagner-Bartak, Nicolaus, MD, Hagemeister, Frederick, Prof, Westin, Jason, MD, Fayad, Luis, MD, Samaniego, Felipe, MD, Turturro, Francesco, Prof, Oki, Yasuhiro, MD, Chen, Wendy, PA, Badillo, Maria, MSN, Nomie, Krystle, PhD, Rosa, Maria DeLa, BS, Zhao, Donglu, MD, Lam, Laura, PhD, Addison, Alicia, MS, Zhang, Hui, BSN, Young, Ken H, MD, Li, Shaoying, MD, Santos, David, MD, Medeiros, L Jeffrey, Prof, Champlin, Richard, Prof, Romaguera, Jorge, Prof, Zhang, Leo, MD

“…Summary Background Ibrutinib is approved in the EU, USA, and other countries for patients with mantle cell lymphoma who received one previous therapy. In a…”
Get full text

Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study by Kantarjian, Hagop, Prof, Thomas, Deborah, MD, Jorgensen, Jeffrey, MD, Jabbour, Elias, MD, Kebriaei, Partow, MD, Rytting, Michael, MD, York, Sergernne, RN, Ravandi, Farhad, MD, Kwari, Monica, RN, Faderl, Stefan, MD, Rios, Mary Beth, RN, Cortes, Jorge, MD, Fayad, Luis, MD, Tarnai, Robert, PhD, Wang, Sa A, MD, Champlin, Richard, MD, Advani, Anjali, MD, O'Brien, Susan, MD

“…Summary Background The outlook for patients with refractory and relapsed acute lymphocytic leukaemia (ALL) is poor. CD22 is highly expressed in patients with…”
Get full text

Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma by Strati, Paolo, Ahmed, Mohamed Amin, Fowler, Nathan H, Nastoupil, Loretta J, Samaniego, Felipe, Fayad, Luis E, Hagemeister, Fredrick B, Romaguera, Jorge E, Rodriguez, Alma, Wang, Michael, Westin, Jason R, Cheah, Chan, Noorani, Mansoor, Feng, Lei, Davis, Richard E, Neelapu, Sattva S

“…The impact of pre-treatment maximum standardized uptake value (SUV ) on the outcome of follicular lymphoma (FL) following specific frontline regimens has not…”
Get full text

Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response by Jallouk, Andrew P, Gouni, Sushanth, Westin, Jason, Feng, Lei, Mistry, Haleigh, Steiner, Raphael E, James, Jinsu, Noorani, Mansoor, Horowitz, Sandra, Puebla-Osorio, Nahum, Fayad, Luis E, Iyer, Swaminathan P, Hawkins, Misha, Flowers, Christopher R, Ahmed, Sairah, Nastoupil, Loretta J, Kebriaei, Partow, Shpall, Elizabeth J, Neelapu, Sattva S, Nieto, Yago, Strati, Paolo

Get full text

Experience with obatoclax mesylate (GX15-070), a small molecule pan–Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma by Oki, Yasuhiro, Copeland, Amanda, Hagemeister, Fredrick, Fayad, Luis E., Fanale, Michelle, Romaguera, Jorge, Younes, Anas

Get full text

Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study by Friedberg, Jonathan W, Cohen, Philip, Chen, Ling, Robinson, K Sue, Forero-Torres, Andres, La Casce, Ann S, Fayad, Luis E, Bessudo, Alberto, Camacho, Elber S, Williams, Michael E, van der Jagt, Richard H, Oliver, Jennifer W, Cheson, Bruce D

“…Bendamustine hydrochloride is an alkylating agent with novel mechanisms of action. This phase II multicenter study evaluated the efficacy and toxicity of…”
Get full text